DelveInsight’s “Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Allergic Rhinitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Allergic Rhinitis Market Forecast
Some of the key facts of the Allergic Rhinitis Market Report:
-
The Allergic Rhinitis market size was valued approximately USD 3,496 million in the United States in the year 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
According to DelveInsight’s projections, the market size in Japan reached roughly USD 2,284 million in 2022. It is anticipated that these figures will rise throughout the forecast period.
-
According to DelveInsight’s evaluation, the total number of diagnosed prevalent cases of Allergic Rhinitis in the 7MM stood at approximately 89 million in 2022, with the US contributing around 25 million cases. It is expected that these cases will rise in the forecast period from 2023 to 2032.
-
The number of diagnosed prevalent cases of AR in the US was estimated to reach 28% of all cases in the 7MM in 2022, and it is anticipated that this number will rise during the course of the study period (2019–2032)
-
The number of diagnosed prevalent instances of AR in 2022 was roughly 6.6 million, 13 million, and 5 million for mild, moderate, and severe cases, respectively. This number is expected to rise during the projected period
-
In November 2022, Hyloris Pharmaceuticals SA has introduced a novel proprietary formulation, specifically a TRPV1 agonist, administered through intranasal spray for the treatment of idiopathic rhinitis. Idiopathic rhinitis is characterized by an excessive expression of TRPV1 in the nasal mucosa, leading to symptoms such as nasal obstruction, rhinorrhea (commonly known as a runny nose), and/or sneezing.
-
In June 2022, Revelation Biosciences Inc. has successfully concluded the enrollment and dosing phase of its Phase Ib CLEAR clinical trial, evaluating the safety and effectiveness of intranasal REVTx-99b in treating allergic rhinitis. REVTx-99b is a proprietary intranasal formulation designed to address allergic rhinitis symptoms, including persistent nasal congestion. In a Phase I clinical study, the active ingredient demonstrated the ability to upregulate a protein that competes with the native eotaxin receptor, CCR3. This process helps prevent the recruitment of eosinophils and basophils by eotaxin, ultimately reducing Th2 cell recruitment and mitigating the allergic response.
-
Certain companies have commenced clinical trials to explore novel treatment avenues, such as Regeneron Pharmaceuticals’ REGN5713-5714-5715 and Grass MATA by Allergy Therapeutics, which are being considered as potential therapies in the DelveInsight therapeutics market model for the seven major markets (7MM).
-
Key Allergic Rhinitis Companies: Regeneron Pharmaceuticals, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB, Hyloris Pharmaceuticals, Revelation Biosciences Inc., Yingu Pharmaceutical, Glenmark Specialty S.A., Pfizer, Oxagen Ltd, Idorsia Pharma, Magna Pharma, Glenmark Specialty, Bayer, and others
-
Key Allergic Rhinitis Therapies: REGN5713- 5714-5715, Grass MATA MPL, MG01 + T517, Levocetirizine, BLX-028914, Bencycloquidium, Dupilumab, GSP 301 NS, PF-03654764, OC000459, ACT-129968, STAHIST, GSP 301, Azelastine hydrochloride (BAYR9258), and others
-
Around 178 million common cases of Allergic Rhinitis in the 7MM and 68 million common cases in the EU4 and the UK were estimated by 2022
-
Some companies have initiated clinical trials investigating new treatment options, including Regeneron Pharmaceuticals’ REGN5713-5714-5715 and Grass MATA by Allergy Therapeutics as the potential therapies lined up for forecast in the 7MM in the DelveInsight therapeutics market model
-
The Allergic Rhinitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Allergic Rhinitis pipeline products will significantly revolutionize the Allergic Rhinitis market dynamics.
Allergic Rhinitis Overview
Allergic rhinitis, commonly known as hay fever, is an allergic response characterized by symptoms such as sneezing, nasal congestion, itching of the nose, and watery eyes. Triggers for hay fever include pollen, pet dander, mold, and insect allergens. Although hay fever symptoms can be distressing, relief can often be found through lifestyle adjustments, allergy medications, and immunotherapy, such as allergy shots.
Get a Free sample for the Allergic Rhinitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/allergic-rhinitis-market
Allergic Rhinitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Allergic Rhinitis Epidemiology Segmentation:
The Allergic Rhinitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Allergic Rhinitis
-
Prevalent Cases of Allergic Rhinitis by severity
-
Gender-specific Prevalence of Allergic Rhinitis
-
Diagnosed Cases of Episodic and Chronic Allergic Rhinitis
Download the report to understand which factors are driving Allergic Rhinitis epidemiology trends @ Allergic Rhinitis Epidemiology Forecast
Allergic Rhinitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Allergic Rhinitis market or expected to get launched during the study period. The analysis covers Allergic Rhinitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Allergic Rhinitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Allergic Rhinitis Therapies and Key Companies
-
REGN5713- 5714-5715: Regeneron Pharmaceuticals
-
Grass MATA MPL: Allergy Therapeutics
-
MG01 + T517: Inmunotek
-
Levocetirizine: UCB Pharma
-
BLX-028914: Orexo AB
-
Bencycloquidium: Yingu Pharmaceutical
-
Dupilumab: Regeneron Pharma
-
GSP 301 NS: Glenmark Specialty S.A.
-
PF-03654764: Pfizer
-
OC000459: Oxagen Ltd
-
ACT-129968: Idorsia Pharma
-
STAHIST: Magna Pharma
-
GSP 301: Glenmark Specialty
-
Azelastine hydrochloride (BAYR9258): Bayer
Discover more about therapies set to grab major Allergic Rhinitis market share @ Allergic Rhinitis Treatment Market
Allergic Rhinitis Market Strengths
-
The increasing prevalence of Allergic Rhinitis will augment the overall treatment and management landscape
Allergic Rhinitis Market Opportunities
-
Beneficial reimbursement policies with severity-based Allergic Rhinitis are expected to accentuate the growth of the treatment market
Scope of the Allergic Rhinitis Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Allergic Rhinitis Companies: Regeneron Pharmaceuticals, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB, Hyloris Pharmaceuticals, Revelation Biosciences Inc., Yingu Pharmaceutical, Glenmark Specialty S.A., Pfizer, Oxagen Ltd, Idorsia Pharma, Magna Pharma, Glenmark Specialty, Bayer, and others
-
Key Allergic Rhinitis Therapies: REGN5713- 5714-5715, Grass MATA MPL, MG01 + T517, Levocetirizine, BLX-028914, Bencycloquidium, Dupilumab, GSP 301 NS, PF-03654764, OC000459, ACT-129968, STAHIST, GSP 301, Azelastine hydrochloride (BAYR9258), and others
-
Allergic Rhinitis Therapeutic Assessment: Allergic Rhinitis current marketed and Allergic Rhinitis emerging therapies
-
Allergic Rhinitis Market Dynamics: Allergic Rhinitis market drivers and Allergic Rhinitis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Allergic Rhinitis Unmet Needs, KOL’s views, Analyst’s views, Allergic Rhinitis Market Access and Reimbursement
To know more about Allergic Rhinitis companies working in the treatment market, visit @ Allergic Rhinitis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Allergic Rhinitis Market Report Introduction
2. Executive Summary for Allergic Rhinitis
3. SWOT analysis of Allergic Rhinitis
4. Allergic Rhinitis Patient Share (%) Overview at a Glance
5. Allergic Rhinitis Market Overview at a Glance
6. Allergic Rhinitis Disease Background and Overview
7. Allergic Rhinitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Allergic Rhinitis
9. Allergic Rhinitis Current Treatment and Medical Practices
10. Allergic Rhinitis Unmet Needs
11. Allergic Rhinitis Emerging Therapies
12. Allergic Rhinitis Market Outlook
13. Country-Wise Allergic Rhinitis Market Analysis (2019–2032)
14. Allergic Rhinitis Market Access and Reimbursement of Therapies
15. Allergic Rhinitis Market Drivers
16. Allergic Rhinitis Market Barriers
17. Allergic Rhinitis Appendix
18. Allergic Rhinitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/